Suresh S. Ramalingam

Emory University

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index125

i10-index481

Publications1,240

Citations106,197

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 127

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Clinical Cancer Research · 2026-06-26
“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality
Cancer · 2026-06-24
Figure S5 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in <i>LKB1</i>-Mutant Lung Cancer
2026-06-17
Figure S2 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in <i>LKB1</i>-Mutant Lung Cancer
2026-06-17
Figure S4 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in <i>LKB1</i>-Mutant Lung Cancer
2026-06-17
Figure S1 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in <i>LKB1</i>-Mutant Lung Cancer
2026-06-17
Figure S3 from Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in <i>LKB1</i>-Mutant Lung Cancer
2026-06-17
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
Future Oncology · 2026-04-27
Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection
Proceedings of the National Academy of Sciences · 2026-04-08
Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion
Nature · 2026-03-25 · 2 citations
Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC
Frontiers in Oncology · 2025-12-08 · 4 citations
Table S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table S5 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table S7 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table S6 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26
Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
2025-11-26

Open author page on OpenAlex →